Search

Your search keyword '"ten Hacken, Elisa"' showing total 27 results

Search Constraints

Start Over You searched for: Author "ten Hacken, Elisa" Remove constraint Author: "ten Hacken, Elisa" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
27 results on '"ten Hacken, Elisa"'

Search Results

1. Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

2. Supplementary Tables and Figures from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

3. Data from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

4. Supplementary Legends from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

5. Data from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

6. Supplementary Tables and Figures from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

7. Supplementary Legends from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

8. Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

9. Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

10. Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

11. Data from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

12. Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

15. Supplementary Tables 1,2,3,4 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

16. Supplementary Figures 1,2,3,4,5 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

17. Supplementary Data from Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia

18. Data from Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia

19. Supplementary Data from Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia

20. Supplementary Data from Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia

21. In VivoModeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

24. Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia

25. SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

26. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Catalog

Books, media, physical & digital resources